Literature DB >> 16601868

Cardiomyopathy in tyrosinaemia type I is common but usually benign.

N Arora1, O Stumper, J Wright, D A Kelly, P J McKiernan.   

Abstract

UNLABELLED: Tyrosinaemia type I (TTI) is an inherited multisystemic disorder of tyrosine metabolism. In addition to hepatic and renal involvement, cardiomyopathy is an important clinical manifestation.
OBJECTIVE: To evaluate the incidence and outcome of cardiomyopathy in TTI. SUBJECTS AND METHODS: A retrospective study was performed of 20 consecutive children with TTI (12 male, 8 female) referred to a single centre between 1986 and 2002. All were initially treated with standard dietary therapy and, since 1992, with nitisinone. The indications for orthotopic liver transplantation (LT) changed during the study. Serial echocardiography was undertaken in all subjects.
RESULTS: 9/20 (45%) children had an acute hepatic presentation. Five (25%) received dietary treatment followed by LT, and 14 (70%) were treated with nitisinone at presentation. 6/20 (30%) had cardiomyopathy at initial assessment, with interventricular septal hypertrophy being the commonest finding (5/6). Cardiomyopathy was significantly less common in those treated initially with nitisinone. After a median follow-up of 3.6 (0.45-13.5) years, 5/6 (83%) had complete resolution of cardiomyopathy and 1/6 showed significant improvement. No child with a normal initial echocardiography subsequently developed cardiomyopathy.
CONCLUSION: Cardiomyopathy is a common manifestation of TTI and it has a favourable long-term outcome. Children initially treated with nitisinone are less likely to develop this complication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601868     DOI: 10.1007/s10545-006-0203-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  29 in total

Review 1.  Cardiomyopathies: from genetics to the prospect of treatment.

Authors:  W M Franz; O J Müller; H A Katus
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

2.  X-linked dilated cardiomyopathy.

Authors:  B A Berko; M Swift
Journal:  N Engl J Med       Date:  1987-05-07       Impact factor: 91.245

3.  Tyrosinaemia type I and hypertrophic obstructive cardiomyopathy.

Authors:  M A Edwards; A Green; A Colli; G Rylance
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

4.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

5.  Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts.

Authors:  R Berger; H Van Faassen; J W Taanman; H De Vries; E Agsteribbe
Journal:  Pediatr Res       Date:  1987-10       Impact factor: 3.756

6.  Cardiac alterations in cirrhosis: reversibility after liver transplantation.

Authors:  Mireia Torregrosa; Santi Aguadé; Laura Dos; Rosa Segura; Antonio Gónzalez; Artur Evangelista; Joan Castell; Carlos Margarit; Rafael Esteban; Jaume Guardia; Joan Genescà
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

7.  Clinical and pathologic study of familial dilated cardiomyopathy.

Authors:  L Mestroni; D Miani; A Di Lenarda; F Silvestri; R Bussani; G Filippi; F Camerini
Journal:  Am J Cardiol       Date:  1990-06-15       Impact factor: 2.778

8.  Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects.

Authors:  R Anan; M Nakagawa; M Miyata; I Higuchi; S Nakao; M Suehara; M Osame; H Tanaka
Journal:  Circulation       Date:  1995-02-15       Impact factor: 29.690

9.  On the enzymic defects in hereditary tyrosinemia.

Authors:  B Lindblad; S Lindstedt; G Steen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

10.  Hemodynamic effects of 5-aminolevulinic acid in humans.

Authors:  M A Herman; J Webber; D Fromm; D Kessel
Journal:  J Photochem Photobiol B       Date:  1998-04       Impact factor: 6.252

View more
  12 in total

1.  Nitisinone in the treatment of hereditary tyrosinaemia type 1.

Authors:  Patrick J McKiernan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening.

Authors:  Bijo Varughese; Dnyanoba Madrewar; Sunil Kumar Polipalli; Seema Kapoor
Journal:  Indian J Clin Biochem       Date:  2021-01-06

3.  Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

Authors:  Yue Tang; Yuanyuan Kong
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

4.  Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients.

Authors:  Ayse Cigdem Aktuglu Zeybek; Ertugrul Kiykim; Salim Neselioglu; Halise Zeynep Iscan; Tanyel Zubarioglu; Mehmet Serif Cansever; Ozcan Erel
Journal:  Pediatr Res       Date:  2021-10-09       Impact factor: 3.953

5.  Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy.

Authors:  Sarar Mohamed; Mohammed A Kambal; Nasir A Al Jurayyan; Abdulrahman Al-Nemri; Amir Babiker; Rana Hasanato; Abdullah S Al-Jarallah
Journal:  BMC Res Notes       Date:  2013-09-09

6.  Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1.

Authors:  Imad Dweikat; Nada Qawasmi; Aysha Najeeb; Mohammad Radwan
Journal:  Metabol Open       Date:  2021-01-28

Review 7.  Recommendations for the management of tyrosinaemia type 1.

Authors:  Corinne de Laet; Carlo Dionisi-Vici; James V Leonard; Patrick McKiernan; Grant Mitchell; Lidia Monti; Hélène Ogier de Baulny; Guillem Pintos-Morell; Ute Spiekerkötter
Journal:  Orphanet J Rare Dis       Date:  2013-01-11       Impact factor: 4.123

8.  Clinical and para clinical findings in the children with tyrosinemia referring for liver transplantation.

Authors:  Seyed Mohsen Dehghani; Mahmood Haghighat; Mohammad Hadi Imanieh; Hossein Karamnejad; Abdorrasoul Malekpour
Journal:  Int J Prev Med       Date:  2013-12

9.  Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.

Authors:  Sebene Mayorandan; Uta Meyer; Gülden Gokcay; Nuria Garcia Segarra; Hélène Ogier de Baulny; Francjan van Spronsen; Jiri Zeman; Corinne de Laet; Ute Spiekerkoetter; Eva Thimm; Arianna Maiorana; Carlo Dionisi-Vici; Dorothea Moeslinger; Michaela Brunner-Krainz; Amelie Sophia Lotz-Havla; José Angel Cocho de Juan; Maria Luz Couce Pico; René Santer; Sabine Scholl-Bürgi; Hanna Mandel; Yngve Thomas Bliksrud; Peter Freisinger; Luis Jose Aldamiz-Echevarria; Michel Hochuli; Matthias Gautschi; Jessica Endig; Jens Jordan; Patrick McKiernan; Stefanie Ernst; Susanne Morlot; Arndt Vogel; Johannes Sander; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-08-01       Impact factor: 4.123

Review 10.  Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Authors:  Jeffrey M Chinsky; Rani Singh; Can Ficicioglu; Clara D M van Karnebeek; Markus Grompe; Grant Mitchell; Susan E Waisbren; Muge Gucsavas-Calikoglu; Melissa P Wasserstein; Katie Coakley; C Ronald Scott
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.